LGND SEC Filings, Earnings & Splits

Invesco Ltd. filed an amended Schedule 13G indicating it beneficially owns 1,520,911 shares (7.6%) of Ligand Pharmaceuticals as of September 30, 2026, a passive investment position.

Ligand Pharmaceuticals filed its quarterly report on Form 10-Q for the period ended September 30, 2026, reporting routine financial results including royalty revenues from products such as Filspari, Kyprolis, and Capvaxive.

Ligand Pharmaceuticals issued a press release announcing its financial results for the three and nine months ended September 30, 2026, furnished as Exhibit 99.1 to this Form 8-K.

Ligand Pharmaceuticals entered into a financing agreement with AvenCell Therapeutics for up to $47 million to support the development of controllable, allogeneic CAR-T therapies for cancer.

Ligand Pharmaceuticals acquired royalty and milestone payment rights related to Santen Pharmaceutical's Ryjunea from Sydnexis for $23 million upfront.

Ligand Pharmaceuticals filed a consent of independent registered public accounting firm (Deloitte & Touche) for incorporation by reference into multiple registration statements, relating to the financial statements of XOMA Royalty Corporation.